The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
International travel If you are traveling internationally, research the customs regulations for your destination regarding injectable medications
Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics
The ultimate pathways whereby these molecular changes may translate into changes in body weight and metabolic (dys)function are yet to be fully disclosed, but alterations in the hypothalamic proteome involved in inflammatory and apoptotic processes, as well as in autophagy and vesicular trafficking, may play a role
Alexandra Sowa, MD SoWell Founder Dual Board-Certified Obesity & Internal Medicine Physician Frequently Asked Questions What are FSA and HSA accounts
Study population The source population encompassed all Danish citizens aged 65 years and older with type-2 diabetes between 2007 and 2018 [11]
.png)
